ITEM 2.02 Results of Operations and Financial Condition.

On November 9, 2021, Intra-Cellular Therapies, Inc. (the "Company") announced its financial results for the third quarter ended September 30, 2021, and provided a corporate update.

A copy of the Company's press release containing such announcements is attached hereto as Exhibit 99.1. The information in the press release set forth under the heading "Third Quarter Financial Highlights," together with the condensed consolidated financial information included in the press release, are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.




ITEM 8.01 Other Events.

In the press release dated November 9, 2021, the Company also provided a corporate update. The information set forth under the headings "Commercial Highlights," "Clinical Highlights" and "About Intra-Cellular Therapies," together with the forward-looking statement disclaimer at the end of the press release, are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

ITEM 9.01 Financial Statements and Exhibits.






(d) Exhibits




Exhibit
Number       Description

99.1           Press release dated November 9, 2021.

104          Cover Page Interactive Data file (embedded within the Inline XBRL
             document).

The press release may contain hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

The portions of the press release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the press release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses